Integer Holdings Corporation (ITGR) Stock Price & Analysis
Integer Holdings Corporation (ITGR) closed at USD 126.56 on Thursday, October 22, 2026, down 0.11% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 126.7; the Oct 22, 2026 session ranged USD 126.56–126.75 on volume of 1,453,986 shares. Market capitalization is $4.30B, with a 52-week range of USD 62–126.83 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ITGR.md
Key facts (ITGR)
- Last four reported quarters (through Jul 3, 2026): revenue $1.84B, net income $128M (7.0% margin), free cash flow $112M (SEC filings).
- Valuation: P/E 33.5x (avg 34.5x at the last 3 fiscal year-ends), EV/EBITDA 17.4x, net debt $1.22B.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $5.2M; 2 not under a Rule 10b5-1 plan ($5.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.00 on a 1–5 scale) (9 analysts), mean target USD 121.8 (range 101–127).
- Total return with dividends: 1Y +71.3% vs S&P 500 +14.9%; 5Y +38.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 1.68, revenue estimate $457M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ITGR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.33B | $1.56B | $1.72B | $1.85B | $1.84B |
| Gross profit | $337M | $346M | $410M | $459M | $500M | — |
| Operating income | $136M | $113M | $163M | $208M | $221M | $179M |
| Net income | $96.8M | $66.4M | $90.7M | $120M | $103M | $128M |
| EPS (diluted) | $2.91 | $1.99 | $2.69 | $3.36 | $2.89 | — |
| Free cash flow | $103M | $41.7M | $60.3M | $99.8M | $105M | $112M |
| Gross margin | 27.6% | 26.0% | 26.3% | 26.7% | 27.0% | — |
| Operating margin | 11.1% | 8.5% | 10.5% | 12.1% | 11.9% | 9.7% |
| Net margin | 7.9% | 5.0% | 5.8% | 7.0% | 5.5% | 7.0% |
| Revenue growth | +13.8% | +9.0% | +16.9% | +10.3% | +8.0% | — |
| Cash + short-term investments | $17.9M | $24.3M | $23.7M | $46.5M | $17.2M | — |
| Total debt | $828M | $925M | $960M | $990M | $1.19B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 3, 2026) (ITGR)
P/E 33.5x · P/S 2.3x · EV/EBITDA 17.4x · EV/Sales 3.0x · P/FCF 38.4x · P/B 2.5x · FCF yield 2.60% · Earnings yield 2.98% · Net debt $1.22B · EV $5.52B
P/E at fiscal year-ends: Dec 2025 27.2x, Dec 2024 39.4x, Dec 2023 36.9x.
Insider sales (SEC Form 4, open-market, last ~7 months) (ITGR)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-14…2026-09-15 | Thor Kirk K | Chief Human Resources Officer | 31,540 | $4.0M | 81.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08 | Senn Andrew | President, Growth & Innovation | 9,408 | $1.2M | 63.5% | No | Too little history (no open-market trades in 2023 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ITGR)
Consensus Hold (mean 3.00 on a 1–5 scale), 9 analysts; mean target USD 121.8 (low 101, high 127).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Benchmark | Downgrade | Buy → Hold | |
| 2026-08-04 | Oppenheimer | Downgrade | Outperform → Perform | |
| 2026-08-04 | Truist Securities | Downgrade | Buy → Hold | $110 → $127 |
| 2026-08-04 | Wells Fargo | Target raised | Equal-Weight | $84 → $127 |
| 2026-08-04 | Freedom Capital Markets | Downgrade | Buy → Hold | |
| 2026-08-03 | Keybanc | Downgrade | Overweight → Sector Weight | |
| 2026-07-22 | Freedom Capital Markets | Initiated | Buy | $112 |
| 2026-07-16 | Truist Securities | Target raised | Buy | $97 → $110 |
| 2026-07-08 | Citigroup | Target raised | Neutral | $92 → $96 |
Total return (dividends reinvested) (ITGR)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +71.3% | +38.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +71.6% | +6.7% |
| Volatility (annualized) | 31.7% | 34.6% |
| Max drawdown | -14.3% (Oct 2025→Oct 2025) | -54.7% (Jan 2025→Oct 2025) |
ITGR revenue by product line (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Cardio & Vascular | $280.3M | 60.4% | -2.3% |
| Cardiac Rhythm Management & Neuromodulation | $173.7M | 37.4% | +1.0% |
| Other Markets | $10.1M | 2.2% | -42.8% |
| Total revenue | $464.1M | 100% | — |
ITGR revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $979.8M | 52.9% | +4.4% |
| Rest Of World | $469.9M | 25.3% | +8.8% |
| Costa Rica | $173.5M | 9.4% | +39.2% |
| Puerto Rico | $131.3M | 7.1% | -4.2% |
| Ireland | $99.2M | 5.3% | +17.5% |
| Total revenue | $1.85B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ITGR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | BOSTON SCIENTIFIC CORP (BSX) | “During 2025, three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.” |
Quoted from the company's 10-K filed Feb 23, 2026.
Companies that name ITGR in their SEC reports
| Relationship to ITGR | Company | Filing | Sentence |
|---|---|---|---|
| customer | Orchestra BioMed Holdings, Inc. (OBIO) | 10-K Mar 12, 2026 | “The Moderato system, comprised of the implantable pulse generator ("IPG") and programmer, was manufactured under an original equipment manufacturer contract by a division of Integer Holdings Corporation ("Integer"), a leading supplier of cardiac rhythm management device components.” |
| customer | Anteris Technologies Global Corp. (AVR) | 10-K Feb 26, 2026 | “We are party to a supply and quality agreement (the "Aran Supply Agreement"), dated November 16, 2021, with Aran Biomedical Teoranta ("Aran") (subsequently acquired by Integer Holdings Corporation) pursuant to which Aran supplies us with certain knitted materials from time to time pursuant to one or more purchase orders and in accordance with reasonable quality requirements provided by us.” |
ITGR customer concentration
In the period ended Jul 3, 2026, 3 direct customers each accounted for at least 10% (18%, 17%, 17%) of revenue, per the company's 10-Q filed Aug 4, 2026. The company does not name them.
ITGR company outlook (results filed Aug 3, 2026)
- “Given the pending transaction, Integer is withdrawing its previously issued financial outlook and will not host its previously scheduled earnings conference call and webcast scheduled for Thursday, August 6, 2026.”
- “For 2025 and 2026, amounts include costs associated with leadership transitions, strategic projects, a stockholder activist matter, the Strategic Review announced during the quarter, pursuant to which we subsequently entered into the definitive agreement described elsewhere herein, and a cyber incident.”
Quoted word-for-word from the SEC 8-K results press release.
ITGR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.68 | $1.69 | -0.2% | $457.2M | 9 |
| Next quarter (ends Dec 2026) | $1.79 | $1.80 | -0.9% | $465.3M | 9 |
| Current fiscal year (ends Dec 2026) | $6.16 | $6.08 | +1.3% | $1.82B | 10 |
| Next fiscal year (ends Dec 2027) | $6.87 | $6.81 | +0.9% | $1.93B | 9 |
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 126.56 |
|---|---|
| Change | ▼ 0.11% (down) |
| Previous Close | USD 126.7 |
| Open | USD 126.77 |
| Day Range | USD 126.56 – 126.75 |
| 52-Week Range | USD 62 – 126.83 |
| Volume | 1,453,986 shares |
| Market Cap | $4.30B |
| Exchange | NYQ |
Technical Analysis (ITGR)
Nexqual's technical model rates ITGR "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 49.49 (neutral) |
| vs SMA50 | Above (USD 126.03) |
| MACD | 0.48 (positive) |
Analyst Ratings (ITGR)
Wall Street analysts rate ITGR "Hold" based on 9 analysts, with a mean price target of USD 121.8 (range USD 101–127), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 121.8 |
| High Target | USD 127 |
| Low Target | USD 101 |
| Buy / Hold / Sell | 0 / 9 / 0 |
Earnings (ITGR)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 1.68 |
| Revenue Estimate | $457.15M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.6 vs est 1.38 ▲ beat |
| 2026-03-31 | USD 1.2 vs est 1.19 ▲ beat |
| 2025-12-31 | USD 1.76 vs est 1.7 ▲ beat |
| 2025-09-30 | USD 1.79 vs est 1.68 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (ITGR)
| Total Revenue | $1.84B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.60% |
| Gross Margin | +26.13% |
| Operating Margin | +10.02% |
| Profit Margin | +6.97% |
| ROE | +7.50% |
| Debt / Equity | 0.79 |
| Current Ratio | 3.73 |
| Total Cash | $21.38M |
| Total Debt | $1.36B |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $111.98M (6.1% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (ITGR)
Nexqual rates Integer Holdings Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 10% (last 12 months) |
| Balance Sheet | Mixed — $21M cash and investments vs $1.24B debt (Jul 2026, SEC) |
| Cash Flow | Solid — FCF $112M (last 4 quarters to Jul 2026, SEC), 6% margin |
| Efficiency | Mixed — ROE 8%, ROA 3.9% |
Ownership (ITGR)
| Insider Ownership | +0.85% |
|---|---|
| Institutional Ownership | +136.93% |
| Shares Outstanding | 34.00M |
| Float | 28.90M |
| Short % of Float | +10.95% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (ITGR)
Integer Holdings Corporation is led by Payman Khales, CEO, President & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| CEO, President & Director | Payman Khales |
|---|---|
| Executive VP & CFO | Diron Smith |
| President of Growth & Innovation | Andrew Senn |
| Executive Vice President of Special Projects | Jim Stephens |
| Director of Investor Relations | Kristen Marie Stewart C.F.A. |
Major Backers & Investors (ITGR)
Notable institutional backers of Integer Holdings Corporation include Invesco, AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund, Nomura Holdings Inc., according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Invesco | 6.61% |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 6.19% |
| Nomura Holdings Inc. | 4.57% |
| Morgan Stanley | 3.96% |
| Irenic Capital Management LP | 3.72% |
| Earnest Partners LLC | 2.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.75% |
| Vanguard Group | 10.51% |
| Dimensional Fund Advisors | 4.79% |
| State Street | 4.16% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From Integer Holdings Corporation's Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Integer develops, manufactures, markets and sells products in multiple countries throughout the world and is therefore subject to regulation by numerous agencies and legislative bodies, including the FDA, European Medicines Agency, Health Product Regulatory Agency, Health Canada, Therapeutics Goods Administration and other comparable foreign counterparts.
- The FDA's Quality Management System Regulation sets forth quality requirements for our sites that includes product design and manufacturing processes, requires the maintenance of certain records, and provides for on-site inspection of our facilities and periodic review by the FDA.
- We have integrated our proprietary technologies in our own products and those of our customers.
- Integer's broad technology and capability portfolio within the peripheral vascular markets enables us to address the full spectrum of devices needed in the diagnoses and treatment of peripheral vascular disease.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory issues resulting from product complaints, recalls or regulatory audits could harm our ability to produce and supply products or bring new products to market.
- Our business exposes us to potential product liability claims, which may take the form of a one-off claim from a single claimant or a class action lawsuit covering multiple claimants.
- We may be subject to intellectual property claims, which could be costly and time consuming and could divert our management's attention from our business operations.
- Legal disputes relating to intellectual property have occurred in the past and may occur in the future.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LIVN | LivaNova PLC | USD 81.27 | ▲ 3.61% |
| IRTC | iRhythm Holdings, Inc. | USD 119.64 | ▲ 5.36% |
| HAE | Haemonetics Corporation | USD 116.16 | ▼ 0.81% |
| NEOG | Neogen Corporation | USD 11.98 | ▲ 1.61% |
| TMDX | TransMedics Group, Inc. | USD 72.06 | ▼ 0.47% |
| UFPT | UFP Technologies, Inc. | USD 297.33 | ▲ 2.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt